top of page
RT Banners (17).png

We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.

 

Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.

  

As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.         

This is an invite only event.

Hosts & Speakers 

  • Twitter
  • LinkedIn
  • icons8-link-60
  • LinkedIn
  • LinkedIn
    • LinkedIn
    • icons8-link-60
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    • LinkedIn
    RT Banners (5).png

    Agenda

    Monday March 4th, 2024

         12:30 PM - 2 PM ET   I   9:30 AM - 11:00 AM PT

    5 minutes

    15 minutes

    15 minutes

    15 minutes

    30 minutes

    Welcome and Consortia Updates

    Indu Navar 

    Keynote : Person living with ALS

    Martha and Paul Beach will share with us the impact of ALS on family, and support and shared-decisions

    Grant Opportunities with the ALS Research Programs 

    Sarah N. Fontaine

    Will present the congressionally directed medical research programs, U.S. Army Medical Research and Development Command 

    EverythingALS Vision 2030 AI Research Hub

    Merit Cudkowicz and Ernest Fraenkel

    Vision: 2030:  a First-of-its-Kind AI Research Hub in ALS

    Panel: 'What It Takes'

    Michelle Crouthamel, Lyle Ostrow, Ernest Fraenkel, David Shulman and Sarah N. Fontaine

    "What It Takes": Making Digital Endpoints and Outcomes Foundational to Powered Studies in 2024 - Perspectives from Researchers, Clinicians, Industry and People with ALS

    Agenda

    Friday March 28th, 2025

         11:30 AM - 1:00 PM ET   I   8:30 AM - 10:00 AM PT

    Welcome, Updates, and Announcements

    Welcoming new consortia members.

    Indu Navar, Founder & CEO, EverythingALS

    Comments from the new Consortia members

    Eric Green, Founder and CEO, Trace Neuroscience

    Andreas Kalmes, Vice President of Drug Development, Revalesio

    AI for Reliable ALSFRS-R Scoring: Reducing Variability in Clinical Trials

    Dr. James Berry, MGH

    SAVA AI -> EverythingALS Clinical Endpoint Tool 

    Dr. Lyle Ostrow, Temple Medicine and Sava Marinkov

    Lou Warnett & David Master, Amazon Web Services

    Reliable Monitoring of Respiratory Function & Progression Prediction using AI/ML

    Demonstration of consortium participation link

    Regeneron, Lily, BMS, EverythingALS Team & Scientific Advisors 

    Regulatory update DDT LOI filing

    Citizen-Driven Trial Excellence (Preparedness) 

    EverythingALS team and Consortia

    END OPEN SESSION

    CONSORTIA MEMBERS' BREAKOUT

    12:35 PM - 1:00 PM ET

    Keynote:  A Mother's Strength - Navigating Life with Her Son’s ALS

    Faith Oremland

          ​

    10 minutes

    05 minutes

    10 minutes



    40 minutes

    20 minutes

    05 minutes

    Next steps and Closing Remarks 

    Indu Navar, Founder & CEO, EverythingALS

    Agenda

    Participants

     

    © 2025 by EverythingALS

    EverythingALS is part of Peter Cohen Foundation, a non-profit 501(c)(3), United States. EIN 84-3055901 

    Email: info@everythingals.org

    bottom of page